Juno Genetics harnesses the power of the very latest DNA sequencing technologies to deliver a best-in-class test for chromosome abnormalities, called PGT[A]seq. Not only does PGT[A]seq measure the amount of DNA from each chromosome with unprecedented accuracy, allowing the number of copies of each chromosome to be determined in the embryo biopsy specimen, but it also detects thousands of variations in the sequence of the DNA from the embryo (known as polymorphisms). Juno was one of the first laboratories in the world to add polymorphism analysis to a PGT-A test. The extra information provided by DNA polymorphisms allows detection of important chromosome abnormalities that are invisible to other PGT-A methods, including triploidy, a common cause of miscarriage. Clinical studies have shown that the Juno PGT[A]seq method succeeds in providing valuable predictive information about an embryo’s capacity to produce a healthy birth, helping to avoid the transfer of abnormal embryos, which will fail to implant, miscarry or produce children affected by chromosomal abnormalities.
